221 related articles for article (PubMed ID: 16268979)
21. [Tailor-made medicine in Helicobacter pylori eradication therapy].
Aoyama N; Shirasaka D; Miki I
Nihon Rinsho; 2003 Jan; 61(1):129-36. PubMed ID: 12607330
[TBL] [Abstract][Full Text] [Related]
22. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
23. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Suzuki T; Matsuo K; Sawaki A; Wakai K; Hirose K; Ito H; Saito T; Nakamura T; Yamao K; Hamajima N; Tajima K
Epidemiol Infect; 2007 Jan; 135(1):171-6. PubMed ID: 16740190
[TBL] [Abstract][Full Text] [Related]
24. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
Kawamura M; Ohara S; Koike T; Iijima K; Suzuki H; Kayaba S; Noguchi K; Abe S; Noguchi M; Shimosegawa T
J Gastroenterol Hepatol; 2007 Feb; 22(2):222-6. PubMed ID: 17295875
[TBL] [Abstract][Full Text] [Related]
26. ABO blood type, Lewis and Secretor genotypes, and chronic atrophic gastritis: a cross-sectional study in Japan.
Shibata A; Hamajima N; Ikehara Y; Saito T; Matsuo K; Katsuda N; Tajima K; Tatematsu M; Tominaga S
Gastric Cancer; 2003; 6(1):8-16. PubMed ID: 12673421
[TBL] [Abstract][Full Text] [Related]
27. Association between serum pepsinogens and polymorphismof PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese.
Goto Y; Ando T; Yamamoto K; Tamakoshi A; El-Omar E; Goto H; Hamajima N
Int J Cancer; 2006 Jan; 118(1):203-8. PubMed ID: 16032704
[TBL] [Abstract][Full Text] [Related]
28. Helicobacter pylori infection and genetic polymorphisms for cancer-related genes in gastric carcinogenesis.
Kato S; Onda M; Matsukura N; Tokunaga A; Matsuda N; Yamashita K; Shields PG
Biomed Pharmacother; 1997; 51(4):145-9. PubMed ID: 9207980
[TBL] [Abstract][Full Text] [Related]
29. Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population.
Asaka M; Kato M; Kudo M; Katagiri M; Nishikawa K; Yoshida J; Takeda H; Miki K
Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S7-10. PubMed ID: 8574741
[TBL] [Abstract][Full Text] [Related]
30. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
31. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
32. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
Shimatani T; Moriwaki M; Xu J; Tazuma S; Inoue M
Dig Liver Dis; 2006 Nov; 38(11):802-8. PubMed ID: 16843075
[TBL] [Abstract][Full Text] [Related]
33. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
34. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
[TBL] [Abstract][Full Text] [Related]
35. Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
Chaudhry AS; Kochhar R; Kohli KK
Indian J Med Res; 2009 Oct; 130(4):437-43. PubMed ID: 19942749
[TBL] [Abstract][Full Text] [Related]
36. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
37. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
[TBL] [Abstract][Full Text] [Related]
38. MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese.
Sugimoto M; Furuta T; Shirai N; Kodaira C; Nishino M; Yamade M; Ikuma M; Sugimura H; Ishizaki T; Hishida A
Life Sci; 2008 Aug; 83(7-8):301-4. PubMed ID: 18644389
[TBL] [Abstract][Full Text] [Related]
39. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
Yang JC; Lin CJ
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):29-41. PubMed ID: 19968574
[TBL] [Abstract][Full Text] [Related]
40. TNF gene polymorphisms and Helicobacter Pylori infection in gastric carcinogenesis in Chinese population.
Li C; Xia B; Yang Y; Li J; Xia HH
Am J Gastroenterol; 2005 Feb; 100(2):290-4. PubMed ID: 15667484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
